Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9 by Yuan, Zhu et al.
oncology reports  26:  237-245,  2011
Abstract. Hur, a ubiquitously expressed member of the 
Hu family, selectively binds and stabilizes Are-containing 
mrnAs encoding proto-oncogenes, cell cycle regulators, 
cytokines and growth factors. the role of Hur and its 
cellular function in breast cancer remains unclear. this study 
aimed to provide new insights into the implication of Hur 
in breast cancer. We show that McF7 and MDA-MB-231 
breast cancer cells stably transfected with a hammerhead 
ribozyme transgene specifically targeted to HuR (MCF7HurKo 
and MDA-MB-231HurKo) have reduced Hur expression both 
at mrnA and protein levels. this study reveals that Hur 
knockdown dramatically reduced cell growth in McF7 cells 
(P<0.001) and invasive properties in MDA-MB-231 cells 
(P<0.001). Furthermore, we report that the decreased cell 
growth rate in McF7 cells is seen together with a reduction 
in cyclin D1 transcript and protein levels and that the change 
in invasiveness in MDA-MB-231 cells seems to be linked 
with decreased MMp-9 levels. our study shows that targeting 
HuR can influence breast cancer cell growth and invasion and 
suggests a role for Hur in vitro in enhancing breast cancer 
cell growth and invasion. these changes may be facilitated 
through changes in the levels of cyclin D1 and MMp-9.
Introduction
The human (Hu) antigen R (HuR), a ubiquitously expressed 
member of the Hu family of rnA-binding proteins, was 
first cloned and identified in 1996 (1) and the human HuR 
gene was found to be localized to human chromosome 
19p13.2 (2). The Hu protein family comprises four vertebrate 
members, the primarily neuronal proteins HuB (Hel-N1), HuC 
(PLE21) and HuD, and the ubiquitously expressed ~34 kDa 
protein HuR (2). As members of the Hu protein family share 
homology with the Drosophila embryonic lethal abnormal 
vision (ELAV) proteins, they are sometimes regarded as the 
Hu/elav family (3). In humans, HuR is widely expressed in all 
proliferating cells, whereas HuB, Huc and HuD are expressed 
in terminally differentiated neurons and are therefore called 
the neuronal Hu proteins (4).
Hur protein contains three highly conserved rnA 
recognition motifs (RRMs) and a variable basic hinge region 
between its RRM2 and RRM3 (5,6). RRM1 and RRM2 were 
found to bind and mediate the AU- and U-rich elements 
(collectively termed ARE) recognition (7) and RRM3 is 
believed to bind the poly (A) tail and help maintain the 
stability of the RNA-protein complex (8). The less conserved 
hinge region is believed to contain sequences that allow Hur 
to shuttle between the nucleus and cytoplasm (6).
Hur has a variety of biological functions, all of which 
are based on its ability to stabilize the labile mrnAs bearing 
the AU- and U-rich elements (ARE) and affect their expression 
(9). Many of such ARE-containing mRNAs encode proto-
oncogenes, cell cycle regulators, cytokines and growth 
factors, which are important in many transient biological 
processes (10). The mechanism of HuR stabilization on target 
mrnAs is believed to be mediated through competition with 
destabilizing Are-Bps. Hur is mainly localized within the 
cell nucleus and its presence in the cytoplasm appears to be 
intimately linked to its mrnA-stabilizing function, thus the 
nucleo-cytoplasm shuttling of Hur is generally assumed as 
the initial and critical step of its stabilizing effects (1,11). HuR 
shuttling structurally relies on a sequence in the hinge region, 
which is denoted as HNS (HuR nucleocytoplasmic shuttling 
sequence) (12). 
numerous Are-containing mrnAs encoding proto-
oncogenes, cell cycle regulators, cytokines and growth factors 
have been reported either to associate with Hur or, further, to 
be post-transcriptionally regulated by HuR (6). Many of them 
encode functionally diverse proteins that are important in 
many transient biological processes including cell growth and 
differentiation, signal transduction, transcriptional and trans-
lational control, hematopoiesis, apoptosis, nutrient transport, 
and metabolism (10). However, the potential contribution of 
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Hur to breast carcinogenesis and tumor progression has not 
been directly investigated. our study provides new insights 
into the biological functions Hur and its role in breast cancer.
In the present study, we examined HuR expression in a 
series of human cancer cell lines. In order to elucidate the role 
and the cellular function of Hur in breast cancer, a ribozyme 
transgene consisting of hammerhead ribozyme and antisense 
specific to HuR was cloned into a pEF6 expression vector and 
transfected into McF7 and MDA-MB-231 cells. the effects 
of Hur knockdown on the human breast cancer cells was 
examined through a series of in vitro tests.
Materials and methods 
Cell lines and materials. Human McF7 and MDA-MB-231 
breast cancer cell lines and human pc-3 prostate cancer cell 
line were obtained from the American type culture collection 
(ATCC, MD, USA). The ZR-751 cell line was purchased from 
the European Collection of Cell Cultures (ECACC, Salisbury, 
UK). the cells were routinely cultured in DMeM/Ham's F12 
with L-Glutamine medium (PAA Laboratories, Somerset, 
UK), supplemented with antibiotics and 10% foetal calf serum 
(PAA Laboratories), and incubated at 37.0˚C, 5% CO2 and 
95% humidity. Monoclonal mouse anti-HuR (SC-5261), anti-
GAPDH (SC-32233), anti-MMP-9 (SC-21733), and polyclonal 
rabbit anti-cyclin D1 IgG (SC-8432) were obtained from Santa 
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Peroxidase-
conjugated anti-mouse and anti-rabbit IgG were purchased 
from Sigma-Aldrich Ltd. (Poole, UK).
Generation of HuR knockdown in breast cancer cell lines. 
Anti-human Hur hammerhead ribozymes were designed 
based on the secondary structure of Hur mrnA, generated 
using the Zuker RNA mFold program (13). The ribozymes 
were synthesized and cloned into a pEF6/V5-His-TOPO 
plasmid vector (Invitrogen, Paisley, UK). Ribozyme trans-
genes and empty peF6 control plasmids were transfected 
into McF7 and MDA-MB-231 cells individually following a 
previously reported procedure (14,15). Following transfection 
and blasticidin selection, cells were subsequently cultured 
in maintenance medium and routinely tested to confirm 
knockdown of Hur expression. McF7 and MDA-MB-231 
cells containing the ribozyme transgenes or the control peF6 
plasmids were designated as McF7HurKo and McF7peF6, 
MDA-MB-231HurKo and MDA-MB-231peF6, respectively. the 
wild-type cells were labelled as McF-7Wt or MDA-MB-231Wt.
RNA extraction and reverse transcription-polymerase chain 
reaction (RT-PCR). rnA was extracted from cells using the 
TRI reagent (Sigma, Dorset, UK). Reverse transcription was 
carried out using the iScript™ cDNA synthesis kit (Bio-Rad, 
CA, USA). PCR conditions were: denaturing at 94˚C for 
40 sec, annealing at 55˚C for 40 sec and extension at 72˚C 
for 80 sec. PCR was conducted over 36 cycles with an initial 
5 min denaturing step (94˚C) and a final 10 min extension 
step (72˚C). PCR products were separated on an agarose gel. 
Primer sequences are provided in Table I.
Quantitative-polymerase chain reaction (Q-PCR). real-time 
quantitative pcr was also used to assess the Hur transcript 
levels present in the control and transfected cell lines as 
previously reported (16). Briefly, the iCycler IQ system 
was used to detect and quantify the number of Hur tran-
scripts in each of the control and transfected cells. transcript 
copy numbers were obtained based on an internal standard 
and normalized against gApDH levels in these samples. 
Conditions for Q-PCR were: an initial 15 min 95˚C period 
followed by 80 cycles of 95˚C for 15 sec, 55˚C for 60 sec and 
72˚C for 20 sec.
SDS-PAGE and Western blotting. Following lysis of cells, equal 
amount of each samples were separated on a 10% acrylamide 
gel. proteins were probed using the respective primary anti-
bodies at a concentration of 1:300 (HuR) and 1:500 (GAPDH) 
and specific peroxidase conjugated secondary antibodies at 
a concentration of 1:1000. protein bands were documented 
using a gel documentation system (UVITech, Cambridge, 
UK).
Immunocytochemical staining. Following overnight incuba-
tion, cells were fixed and then permeabilized with 0.1% 
triton X100 for 5 min in tBs. Following blocking with 
horseserum in Super Sensitive™ Wash Buffer (BioGenex, 
UsA), immunochemical staining was performed using the 
primary antibody at a concentration of 1:100 and Vectastain 
Universal Elite ABC kit (Vectastain® ABC system, Vector 
Laboratories, Inc., Nottingham, UK). Intensity of the staining 
was quantified by using the area morphometry of the Optimas 
image analysis software (Optimas version 6.0, Optimas, WA, 
UsA).
In vitro growth assay. cells were incubated for 1, 3 and 5 days 
before being fixed in 4% formaldehyde (v/v) and stained with 
0.5% (w/v) crystal violet. The crystal violet stain was then 
extracted using 10% acetic acid (v/v) and cell density was 
determined by measuring the absorbance of this solution at 
a wavelength of 540 nm using an ELx800 spectrophotometer 
(Bio-Tek Instruments Inc., Winooski, VT, USA).
In vitro Matrigel invasion assay (17). Briefly, 15,000 cells were 
seeded into trans-well inserts (Becton Dickinson Labware, NJ, 
USA), containing 8.0 µm pores, which had been coated with 
50 µg/insert of Matrigel Matrix Basement Membrane (BD 
Biosciences, oxford, UK). After 72 h of incubation, cells which 
had invaded through the artificial basement membrane to the 
outside of the trans-well insert were stained and counted.
In vitro Matrigel adhesion assay (18). Briefly, 45,000 cells were 
seeded into the wells of a 96-well plate that had been pre-coated 
with 5 µg of Matrigel. After 45 min of incubation, non-adherent 
cells were removed by vigorous washing. Adherent cells were 
then stained and counted. 
In vitro migration/wound healing assay (19). cells were 
cultured in a 24-well plate, upon reaching confluence; the cell 
monolayer was wounded using a 21g needle. Digital images 
of a set area were taken using a GXCAM-5 scientific imaging 
camera (GTVision, Suffolk, UK) every 15 min for a 90-min 
period. cell migration into the wound was then calculated 
using ImageJ analysis software.
oncology reports  26:  237-245,  2011 239
Statistical analysis. experimental procedures were repeated 
independently as least 3 times. Data were analysed using the 
Minitab 14 software and statistical comparisons were drawn 
using the two-sample, two-tailed t-test or the Mann-Whitney 
non-parametric test.
Results
The expression of HuR in breast cancer cell lines. the presence 
of Hur was examined in 4 human cancer cell lines through 
reverse transcription-PCR (RT-PCR). The expression of 
HuR was relatively high in the breast cell lines (MCF7, 
MDA-MB-231 and Zr-75-1) and the prostate cancer cell 
line (PC-3) examined (Fig. 1). To investigate the biological 
function of Hur in breast cancer, two of the examined cell 
lines were chosen for knockdown studies. McF7 cells are 
derived from a metastatic pleural effusion of a female patient 
with breast cancer. McF7 is an adherent cell line with an 
epithelial morphology and is estrogen receptor positive. the 
MDA-MB-231 cell line is derived from a pleural effusion of 
a female patient with metastatic breast cancer. MDA-MB-231 
cells are adherent and epithelial in morphology. the cell line 
is estrogen receptor negative and is highly tumorigenic.
Manipulation of HuR expression by ribozyme transgene. 
RT-PCR and Q-PCR demonstrated that HuR mRNA expression 
was successfully knocked down in McF7HurKo and MDA-MB-
231HurKo cells in comparison to the level of expression in 
wild-type cells (MCF7Wt and MDA-MB-231Wt) and in empty 
plasmid cells (MCF7peF6 and MDA-MB-231peF6) (Fig. 2A 
and  B). Additionally, Western blotting was used to probe for 
Hur protein levels in both the control and transfected cell lines. 
similar to the trends seen at the mrnA level, Hur protein 
was found to be highly expressed in all of the control cell lines 
(MCF7Wt, MDA-MB-231Wt, McF7peF6 and MDA-MB-231peF6) 
and expression of Hur protein exhibited a dramatic reduction in 
the transfected cell lines (MCF7HurKo and MDA-MB-231HurKo) 
(Fig. 2C). Immunocytochemical (ICC) staining indicated a 
decrease in Hur protein levels in both MDA-MB-231 and 
Table I. Primers used for RT-PCR or Q-PCR in the present study.
Gene of           Primer name Primer sequence (5'-3') Optimal annealing
interest   temperature (˚C)
HuR     HuR-F8 gagctcagaggtgatcaaag 55
     HuR-R8 ttgtagatgaaaatgcacca
Hur ribozyme 1     Hurrib1F ctgcagcatacgacaccttaatggttttctgatgagtccgtgagga 55
     Hurrib1r actagtgaacggcttgaggctccagtttcgtcctcacggact
Hur ribozyme 2     Hurrib2F ctgcagctcgggcgagcatacctgatgagtccgtgagga 55
     Hurrib2r actagtcaaaaaccattaaggtgtttcgtcctcacggact
Hur ribozyme 3     Hurrib3F ctgcaggacccgcgagttgatctgatgagtccgtgagga 55
     Hurrib3r actagttctctcggtttgggcggatttcgtcctcacggact
Hur ribozyme 4     Hurrib4F ctgcagatccacgaggacccgcgagttctgatgagtccgtgagga 55
     Hurrib4r actagtcggtttgggcggatcatttcgtcctcacggact
gApDH     F8 ggctgcttttaactctggta 55
     R8 gactgtggtcatgagtcctt
gApDH (Q-PCR)     gApDH F2 ctgagtacgtcgtggagtc 55
     gApDH Zr2 actgaacctgaccgtacacagagatgaccctttg
cyclin D1     cyclin D1 F1 cggtgtcctacttcaaatgt 55
     cyclin D1 Zr actgaacctgaccgtacaaagcggtccaggtagttc
     cyclin D1 r1 acctcctcctcctcctct
MMp-9     MMp-9 F1 aactacgaccgggacaag 55
     MMp-9 r1 attcacgtcgtccttatgc
     MMp-9 Zr1 actgaacctgaccgtacaggaaagtgaaggggaaga
Figure 1. expression of Hur in breast and prostate cancer cell lines. the 
presence of Hur was examined in 4 human cancer cell lines using rt-pcr. 
HuR was highly expressed in all breast (MCF7, MDA-MB-231 and ZR-751) 
and prostate (PC-3) cell lines tested.
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McF7 cells transfected with the ribozyme transgene versus 
their respective controls (Fig. 2D).
HuR has differing effects on cell growth. effects of Hur 
on the growth of McF7 and MDA-MB-231 were examined 
using an in vitro tumor cell growth assay. contrasting results 
for the effects of Hur expression on tumor cell growth were 
seen between the MCF7 and MDA-MB-231 cell lines. In the 
MCF7 cell line, knockdown of HuR resulted in a significant 
decrease in growth and a significant difference was seen 
between the McF7HurKo and McF7peF6 cell line after 3- and 
5-day incubation periods (day 3: 62.5±21.2 vs. 249.7±48.4 
P<0.001, day 5: 163.6±35.4 vs. 416.5±42.9 P<0.001) (Fig. 3A). 
strangely, the MDA-MB-231 cell line did not follow a similar 
trend and no significant difference in growth was seen between 
the MDA-MB-231HurKo and MDA-MB-231peF6 cell lines over 
the 5-day incubation period (day 3: 284.1±14.8 vs. 301.0±53.5 
P>0.05, day 5: 866.2±67.7 vs. 719.3±76.7 P>0.05) (Fig. 3B).
HuR expression does not alter cell adhesion. the capacity 
of McF7 and MDA-MB-231 breast cancer cells to adhere 
to an artificial Matrigel basement membrane over a 45-min 
period was examined using an in vitro Matrigel adhesion 
assay. transfection with the Hur ribozyme transgene plasmids 
was not seen to affect the adhesive properties of either McF7 
or MDA-MB-231 cells to an artificial Matrigel basement 
membrane over a 45-min incubation period (Fig. 3C and D). No 
significant difference in adhesive capacity was seen between 
cells containing the ribozyme transgene plasmids and their 
respective pEF6 control cells (MCF7HurKo vs. McF7peF6, 
18.25±2.96 vs. 17.13±2.70, P>0.05; MDA-MB-231HurKo vs. 
MDA-MB-231peF6, 57.88±8.71 vs. 67.38±9.93, P>0.05). 
Figure 2. Transfection with HuR ribozyme transgene successfully reduced levels in MCF7 and MDA-MB-231 breast cancer cell lines. (A) HuR mRNA was 
qualitatively detected using rt-pcr and demonstrated a reduction in Hur expression in McF7HurKo and MDA-MB-231HurKo cells compared to controls. 
(B) Q-PCR was subsequently used to confirm the decrease of HuR mRNA transcript in MCF7HurKo and MDA-MB-231HurKo cell lines. (C) Western blotting 
showed a similar decrease in Hur protein levels in the McF7HurKo and MDA-MB-231HurKo in comparison to controls. (D) Immunocytochemical staining 
indicated Hur protein levels were decreased by the ribozyme transgene.
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Loss of endogenous HuR results in differing cell invasion. no 
significant difference in cellular invasion was seen between the 
McF7HurKo and McF7peF6 cell lines over the 3-day incuba-
tion period (15.67±2.07 vs. 18.33±2.66, P>0.05) (Fig. 4A). 
In contrast, loss of endogenous HuR resulted in a dramatic 
reduction in the invasiveness of MDA-MB-231 cells (Fig. 4B). 
MDA-MB-231HurKo was found to have a significantly reduced 
capacity to invade through an artificial Matrigel basement 
Figure 3. Impact of HuR suppression on cell growth and adhesion of MCF7 and MDA-MB-231 cells. (A) Knockdown of HuR significantly reduced the 
growth rate of MCF7 cells (P<0.001). (B) In contrast, knockdown of HuR did not affect the growth of MDA-MB-231 cells. (C and D) Knockdown of HuR was 
not seen to affect the adhesion of McF7 and MDA-MB-231 cells.
Figure 4. Impact of HuR suppression on cellular invasion and migration of MCF7 and MDA-MB-231 cells. (A) No significant difference in cellular invasion 
was seen between McF7HurKo and McF7peF6 cell lines over the 3-day incubation period (P>0.05). (B) In contrast, knockdown of HuR significantly reduced 
the invasiveness of MDA-MB-231 cells compared to the control (P<0.001). (C and D) Knockdown of HuR did not retard the migration of either MCF7 or 
MDA-MB-231 cells.
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membrane compared to its respective control cells (6.67±2.16 
vs. 18.17±2.93, P<0.001).
Knockdown of HuR does not influence cell migration. the 
effect of Hur expression on cell migration was assessed 
using a migration/wounding assay. Knockdown of Hur did 
not influence the migration of either MCF7 or MDA-MB-231 
cells (Fig. 4C and D). No significant difference in migratory 
rates was seen between either McF7HurKo or MDA-MB-
231HurKo and their respective pEF6 controls (MCF7HurKo 
vs. McF7peF6, 47.4±12.7 vs. 39.36±1.66, P=0.34 at 90 min; 
MDA-MB-231HurKo vs. MDA-MB-231peF6, 56.85±4.94 vs. 
51.0±15.5, P=0.56 at 90 min).
Knockdown of HuR correlates with down-regulation 
Cyclin D1. cyclin D1, as a target mrnA of Hur, is one of the 
more frequently altered cell cycle regulators in cancers (20), 
thus, we assumed an association of Hur's effect on tumor 
cell growth with the cell cycle regulator cyclin D1, and we 
examined the cyclin D1 expression at mrnA and protein level 
in both the control and transfected breast cancer cells. our 
study showed that cyclin D1 transcription was down-regulated 
with loss of endogenous Hur expression in McF7 cells. 
Conventional RT-PCR, Q-PCR and Western blot revealed 
lower mrnA and protein levels of cyclin D1 in McF7HurKo 
cells compared to McF7Wt and McF7peF6 cells (Fig. 5A-C). 
There was decreased ICC staining of cyclin D1 in MCF7HurKo 
Figure 5. Knockdown of Hur can impact on cyclin D1 levels. cyclin D1 transcription was down-regulated with loss of endogenous Hur expression in 
MCF7 cells. (A-C) Conventional RT-PCR, Q-PCR and Western blotting reveal lower mRNA and protein levels of cyclin D1 in MCF7HurKo cells compared 
to McF7Wt and McF7peF6 cells. (D) There was decreased ICC staining of cyclin D1 in MCF7HurKo cells compared with that in McF7Wt and McF7peF6. no 
similar trend of cyclin D1 at mrnA and protein levels was seen in MDA-MB-231 cell lines.
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cells, compared with that in McF7Wt and McF7peF6 (Fig. 5D). 
no similar trend of cyclin D1 at mrnA and protein levels was 
seen in MDA-MB-231 cell lines (Fig. 5).
Knockdown of HuR correlates with reduction of MMP-9. 
previous studies have indicated the importance of MMp-9 
in cancer cell invasion and metastasis (21). In order to gain 
insight into mechanisms whereby Hur may promote breast 
cancer cell invasion, we examined the levels of MMp-9 
expression at both transcript and protein level in control 
and Hur suppressed breast cancer cells. A decreased level 
of MMp-9 mrnA was observed in MDA-MB-231 cells 
containing the Hur ribozyme transgenes. concordant 
with this decrease in mrnA level, there was a decreased 
protein level (Fig. 6A-C). Decreased ICC staining of MMP-9 
is also seen in MDA-MB-231HurKo cells, compared with 
that in MDA-MB-231Wt and MDA-MB-231peF6 (Fig. 6D). 
Interestingly, no similar reduction of MMP-9 expression 
at mrnA and protein levels was seen in McF7HurKo cells 
compared to the respective wild-type and peF6 control cells 
(Fig. 6).
Discussion
normal human cells become neoplastic by progressively 
acquiring mutations in cancer genes, these mutations sub-
sequently provide the cell with a competitive growth advantage 
via different cancer-cell phenotypes (22,23). A variety of target 
Figure 6. Knockdown of HuR can impact on MMP-9 levels. (A-C) A decreased level of MMP-9 mRNA and protein was observed in MDA-MB-231 cells 
containing the HuR ribozyme transgene. (D) ICC staining revealed a decreased staining intensity of MMP-9 in MDA-MB-231HurKo cells compared with that 
in MDA-MB-231Wt and MDA-MB-231peF6. no similar reduction of MMp-9 expression at mrnA and protein levels was seen in McF7HurKo cells compared to 
its respective wild-type and peF6 control cells.
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mrnAs bound and stabilized by Hur are related to cancer. 
Many of such target mrnAs encode cell cycle regulators 
and proto-oncogenes such as cyclin A, cyclin B1, cyclin D1, 
c-myc and c-fos (24-26), growth factors such as EGF (27) 
and GM-CSF (28), as well as other factors and cytokines 
that influence tumour progression such as HIF-1α (27), 
VEGF (29), uPA (30), MMP-9 and MTA1 (31). Through its 
association with such target mrnAs, Hur is found to play a 
pivotal role in the carcinogenesis and subsequent progression 
via diverse cancer-cell phenotypes: enhanced cell division, 
resistance of apoptosis, maintenance of angiogenesis, invasion 
of tissues and metastasis, and evasion of antitumor immune 
responses (32).
Despite Hur's ability to bind to and enhance the expression 
of mrnAs that play pivotal roles in cell growth and prolifera-
tion, transcriptional and translational control, hematopoiesis 
and apoptosis, its potential contribution to carcinogenesis 
and tumor progression in breast cancer has not been directly 
investigated. In order to elucidate the functional importance 
of Hur in breast cancer, our studies have led to the generation 
of human breast cancer cell lines (MCF7 and MDA-MB-
231) containing anti-human Hur hammerhead ribozyme 
transgenes and a reduced expression of Hur transcript and 
protein levels. 
The present study shows that knockdown of HuR signifi-
cantly decreased the growth rate of McF7 cells over a 5-day 
incubation period; however, this trend was not mimicked in 
the MDA-MB-231 cells. Additionally, we demonstrate that 
Hur knockdown resulted in a dramatic reduction of the 
cellular invasiveness of MDA-MB-231 cells; however, the 
same trend was not seen in McF7 cells. the exact reason 
behind this differential effect of Hur on the growth and 
invasion of these two breast cancer cell lines is currently 
unknown. It is likely that the differential growth effects 
may be due to differences in the expression patterns of other 
proteins between the McF7 and MDA-MB-231 cell lines. We 
also report that knockdown of Hur does not alter the adhesive 
properties and migration capability of the two breast cancer 
cell lines.
In order to gain insight into the mechanisms whereby HuR 
may have its promoting effect on breast cancer cell growth, 
a series of growth factors and known target mrnAs of Hur 
were examined in McF7 and MDA-MB-231 cells with and 
without the ribozyme transgenes. the data shows that the 
expression of cyclin D1 is correlated to Hur expression at 
mrnA and protein levels in the McF7 cell line. However, no 
such correlation of cyclin D1 expression with Hur was found 
in the MDA-MB-231 cell line. cyclin D1, which functions 
as a mitogenic sensor and allosteric activator of cDK4 or 
CDK6 (33), is one of the more frequently altered cell cycle 
regulators in cancers (20). Cyclin D1 mRNA, as a target 
mrnA of Hur, has been found to be bound and stabilized by 
HuR (25). Cyclin D1 overexpression is implicated as a driving 
feature in various types of cancer, including non-small cell 
lung cancer (34), breast cancer (35), and oesophageal cancer 
(36). Cyclin D1 overexpression in human tumors is driven 
by multiple mechanisms comprising genomic alterations, 
post-transcriptional regulation, and post-translational protein 
stabilization (20). Based on these findings and the present 
results, we support the association of Hur's effect on tumor 
cell growth with cell cycle regulator cyclin D1, and suggest 
that HuR may influence the growth rate of breast cancer cells 
in vitro through the regulation of cyclin D1.
previous studies have highlighted the importance of 
MMP-9 in cancer cell invasion and metastasis (21) and the 
ability of HuR to stabilise MMP-9 mRNA (32). Thus, to 
clarify whether HuR's influence over MMP-9 is responsible 
for the reduced invasion seen here in MDA-MB-231 cells we 
examined the levels of MMp-9 expression at both transcript 
and protein level in control and Hur suppressed breast cancer 
cells. The data indicated that there was a significant decrease 
of MMp-9 mrnA in MDA-MB-231HurKo cells compared to 
MDA-MB-231Wt and MDA-MB-231peF6 cells, concordant 
with this decrease in the mrnA level, a decrease in protein 
level was also seen. these results further support the role of 
Hur in stabilizing expression levels of MMp-9 and suggest 
that in the aggressive MDA-MB-231 breast cancer cell line 
this mechanism may be responsible, at least partially, for the 
reduced invasiveness seen in Hur knockdown cells. together, 
this study suggests a role of Hur in the enhancement of 
cellular invasion, a key event in invasion and metastasis of 
breast cancer, and implies that Hur may affect the cellular 
invasion of breast cancer cells by regulating MMp-9.
In summary, our studies indicate that HuR can enhance 
breast cancer cell growth and invasion in vitro and this 
appears to be facilitated by changes in the level of cyclin 
D1 and MMp-9. Additional research using in vivo models is 
required to fully elucidate the mechanisms and role(s) of HuR 
in breast carcinogenesis and tumor progression.
Acknowledgements 
Dr Z. yuan, current in Beijing Friendship Hospital is a 
recipient of cardiff University china Medical scholarship. 
the authors wish to thank the Albert Hung Foundation, 
cancer research Wales and Beijing Friendship Hospital 
research Fund for supporting their work.
References 
  1. Ma WJ, cheng s, campbell c, Wright A and Furneaux H: 
cloning and characterization of Hur, a ubiquitously expressed 
Elav-like protein. J Biol Chem 271: 8144-8151, 1996.
  2. Ma WJ and Furneaux H: localization of the human Hur gene to 
chromosome 19p13.2. Hum genet 99: 32-33, 1997.
  3. yao KM, samson Ml, reeves r and White K: gene elav of 
Drosophila melanogaster: a prototype for neuronal-specific 
RNA binding protein gene family that is conserved in flies and 
humans. J neurobiol 24: 723-739, 1993.
  4. peng ss, chen cy, Xu n and shyu AB: rnA stabilization by 
the AU-rich element binding protein, HuR, an ELAV protein. 
EMBO J 17: 3461-3470, 1998.
  5. okano HJ and Darnell rB: A hierarchy of Hu rnA binding 
proteins in developing and adult neurons. J neurosci 17: 3024-
3037, 1997.
  6. Brennan cM and steitz JA: Hur and mrnA stability. cell Mol 
Life Sci 58: 266-277, 2001.
  7. Inoue M, Muto Y, Sakamoto H and Yokoyama S: NMR studies 
on functional structures of the AU-rich element-binding domains 
of Hu antigen C. Nucleic Acids Res 28: 1743-1750, 2000.
  8. Beckel-Mitchener AC, Miera A, Keller R and Perrone-
Bizzozero NI: Poly(A) tail length-dependent stabilization of 
gAp-43 mrnA by the rnA-binding protein HuD. J Biol chem 
277: 27996-28002, 2002.
  9. Myer VE, Fan XC and Steitz JA: Identification of HuR as a 
protein implicated in AUUUA-mediated mrnA decay. eMBo J 
16: 2130-2139, 1997.
oncology reports  26:  237-245,  2011 245
10. Bakheet t, Williams Br and Khabar Ks: AreD 2.0: an update 
of AU-rich element mrnA database. nucleic Acids res 31: 
421-423, 2003.
11. Antic D and Keene JD: embryonic lethal abnormal visual 
rnA-binding proteins involved in growth, differentiation, 
and posttranscriptional gene expression. Am J Hum genet 61: 
273-278, 1997.
12. Fan Xc and steitz JA: overexpression of Hur, a nuclear-
cytoplasmic shuttling protein, increases the in vivo stability of 
ARE-containing mRNAs. EMBO J 17: 3448-3460, 1998.
13. Zuker M: Mfold web server for nucleic acid folding and hybrid-
ization prediction. nucleic Acids res 31: 3406-3415, 2003.
14. Jiang WG, Davies G and Fodstad O: Com-1/P8 in oestrogen 
regulated growth of breast cancer cells, the er-beta connection. 
Biochem Biophys res commun 330: 253-262, 2005.
15. Jiang Wg, Martin tA, lewis-russell JM, Douglas-Jones A, 
ye l and Mansel re: eplin-alpha expression in human breast 
cancer, the impact on cellular migration and clinical outcome. 
Mol Cancer 7: 71, 2008.
16. sanders AJ, parr c, Mason MD and Jiang Wg: suppression of 
hepatocyte growth factor activator inhibitor-1 leads to a more 
aggressive phenotype of prostate cancer cells in vitro. Int J Mol 
Med 20: 613-619, 2007.
17. Jiang Wg, Hiscox s, Hallett MB, Horrobin DF, Mansel re 
and puntis Mc: regulation of the expression of e-cadherin on 
human cancer cells by gamma-linolenic acid (GLA). Cancer Res 
55: 5043-5048, 1995.
18. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF and 
Puntis MC: Inhibition of hepatocyte growth factor-induced 
motility and in vitro invasion of human colon cancer cells by 
gamma-linolenic acid. Br J cancer 71: 744-752, 1995.
19. Jiang Wg, Hiscox se, parr c, et al: Antagonistic effect of nK4, 
a novel hepatocyte growth factor variant, on in vitro angio-
genesis of human vascular endothelial cells. clin cancer res 5: 
3695-3703, 1999.
20. Kim JK and Diehl JA: nuclear cyclin D1: an oncogenic driver in 
human cancer. J cell physiol 220: 292-296, 2009.
21. yao J, Xiong s, Klos K, et al: Multiple signaling pathways 
involved in activation of matrix metalloproteinase-9 (MMP-9) 
by heregulin-beta1 in human breast cancer cells. oncogene 20: 
8066-8074, 2001.
22. Hanahan D and Weinberg rA: the hallmarks of cancer. cell 
100: 57-70, 2000.
23. Vogelstein B and Kinzler KW: Cancer genes and the pathways 
they control. Nat Med 10: 789-799, 2004.
24. lal A, Mazan-Mamczarz K, Kawai t, yang X, Martindale Jl 
and gorospe M: concurrent versus individual binding of Hur 
and AUF1 to common labile target mrnAs. eMBo J 23: 
3092-3102, 2004.
25. Wang W, caldwell Mc, lin s, Furneaux H and gorospe M: 
Hur regulates cyclin A and cyclin B1 mrnA stability during 
cell proliferation. eMBo J 19: 2340-2350, 2000.
26. Wang W, Yang X, Cristofalo VJ, Holbrook NJ and Gorospe M: 
loss of Hur is linked to reduced expression of proliferative 
genes during replicative senescence. Mol Cell Biol 21: 5889-5898, 
2001.
27. Sheflin LG, Zou AP and Spaulding SW: Androgens regulate 
the binding of endogenous Hur to the AU-rich 3'Utrs of 
HIF-1alpha and EGF mRNA. Biochem Biophys Res Commun 
322: 644-651, 2004.
28. Esnault S and Malter JS: Hyaluronic acid or TNF-alpha plus 
fibronectin triggers granulocyte macrophage-colony-stimulating 
factor mrnA stabilization in eosinophils yet engages differential 
intracellular pathways and mRNA binding proteins. J Immunol 
171: 6780-6787, 2003.
29. levy ns, chung s, Furneaux H and levy Ap: Hypoxic 
stabilization of vascular endothelial growth factor mrnA by the 
RNA-binding protein HuR. J Biol Chem 273: 6417-6423, 1998.
30. tran H, Maurer F and nagamine y: stabilization of urokinase 
and urokinase receptor mrnAs by Hur is linked to its cyto-
plasmic accumulation induced by activated mitogen-activated 
protein kinase-activated protein kinase 2. Mol cell Biol 23: 
7177-7188, 2003.
31. Lopez de Silanes I, Zhan M, Lal A, Yang X and Gorospe M: 
Identification of a target RNA motif for RNA-binding protein 
HuR. Proc Natl Acad Sci USA 101: 2987-2992, 2004.
32. Lopez de Silanes I, Lal A and Gorospe M: HuR: post-tran-
scriptional paths to malignancy. rnA Biol 2: 11-13, 2005.
33. sherr cJ: Mammalian g1 cyclins. cell 73: 1059-1065, 1993.
34. Jin M, Inoue S, Umemura T, et al: cyclin D1, p16 and retino-
blastoma gene product expression as a predictor for prognosis 
in non-small cell lung cancer at stages I and II. Lung Cancer 34: 
207-218, 2001.
35. Barnes DM and gillett ce: cyclin D1 in breast cancer. Breast 
Cancer Res Treat 52: 1-15, 1998.
36. shamma A, Doki y, shiozaki H, et al: cyclin D1 overexpression 
in esophageal dysplasia: a possible biomarker for carcinogenesis 
of esophageal squamous cell carcinoma. Int J Oncol 16: 261-266, 
2000.
